ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-3-27-34ojrdrt-463Research ArticleЛУЧЕВАЯ ТЕРАПИЯRADIOTHERAPYАктуальные направления обеспечения адресной доставки борадля бор-нейтронозахватной терапииPriority Research Directions in Tumor-Targeted Boron Delivery for Boron Neutron Capture Therapyhttps://orcid.org/0000-0001-5398-0565СычеваН. Н.SychevaN. N.

69120 Гейдельберг, Нойенхаймер Фельд, 280

280 Neuenheimer Feld, Heidelberg 69120

https://orcid.org/0000-0002-5631-9016ЛипенгольцА. А.LipengoltsA. A.

Липенгольц Алексей Андреевич, +7 (903) 173-88-77 

115478, Москва, Каширское шоссе, 24 

115409, Москва, Каширское шоссе, 31 

119991, Москва, Ленинский проспект, 31 

Aleksey Lipengolts, +7 (903) 173-88-77 

24 Kashirskoye Shosse, Moscow, 115478 

31 Kashirskoe Shosse, Moscow 115409 

31 Leninsky prospect, Moscow 119991 

lipengolts@mail.ruhttps://orcid.org/0000-0003-2942-7895СкрибицкийВ. А.SkribitskyV. A.

115478, Москва, Каширское шоссе, 24 

115409, Москва, Каширское шоссе, 31 

119991, Москва, Ленинский проспект, 31 

24 Kashirskoye Shosse, Moscow, 115478 

31 Kashirskoe Shosse, Moscow 115409 

31 Leninsky prospect, Moscow 119991 

https://orcid.org/0000-0003-0246-1794ШпаковаК. Е.ShpakovaK. E.

115478, Москва, Каширское шоссе, 24 

115409, Москва, Каширское шоссе, 31 

119991, Москва, Ленинский проспект, 31 

24 Kashirskoye Shosse, Moscow, 115478 

31 Kashirskoe Shosse, Moscow 115409 

31 Leninsky prospect, Moscow 119991 

https://orcid.org/0000-0002-5144-1039ФиногеноваЮ. А.FinogenovaYu. A.

115478, Москва, Каширское шоссе, 24 

119991, Москва, Ленинский проспект, 31 

24 Kashirskoye Shosse, Moscow, 115478 

31 Leninsky prospect, Moscow 119991 

https://orcid.org/0000-0003-0386-9732СмирноваА. В.SmirnovaA. V.

115478 Москва, Каширское шоссе, 24 

111123, Москва, ул. Новогиреевская, 1 

24 Kashirskoye Shosse, Moscow, 115478 

86 Shosse Entuziastov, Moscow 111123 

https://orcid.org/0009-0004-0248-9126КасьяновА. А.KasianovA. A.

115478, Москва, Каширское шоссе, 24 

115409, Москва, Каширское шоссе, 31 

24 Kashirskoye Shosse, Moscow, Russia 115478

31 Kashirskoe Shosse, Moscow 115409

https://orcid.org/0000-0001-7726-7991ГригорьеваЕ. Ю.GrigorievaE. Yu.

115478, Москва, Каширское шоссе, 24 

24 Kashirskoye Shosse, Moscow, 115478

Немецкий центр исследования ракаГерманияClinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ)GermanyНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России ; Национальный исследовательский ядерный университет «МИФИ» ; Институт общей и неорганической химии им. Н.С. Курнакова РАНРоссияN.N. Blokhin National Medical Research Center of Oncology ; National Research Nuclear University MEPhI ; Kurnakov Institute of General and Inorganic ChemistryRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России ; Институт общей и неорганической химии им. Н.С. Курнакова РАНРоссияN.N. Blokhin National Medical Research Center of Oncology ; Kurnakov Institute of General and Inorganic ChemistryRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России ; Московский клинический научно-практический центр им. А.С. Логинова ДЗМРоссияN.N. Blokhin National Medical Research Center of Oncology ; A.S. Loginov Moscow Clinical Scientific CenterRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России ; Национальный исследовательский ядерный университет «МИФИ»РоссияN.N. Blokhin National Medical Research Center of Oncology ; National Research Nuclear University MEPhIRussian FederationНациональный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202523092025832734Copyright © Сычева Н.Н., Липенгольц А.А., Скрибицкий В.А., Шпакова К.Е., Финогенова Ю.А., Смирнова А.В., Касьянов А.А., Григорьева Е.Ю., 20252025Сычева Н.Н., Липенгольц А.А., Скрибицкий В.А., Шпакова К.Е., Финогенова Ю.А., Смирнова А.В., Касьянов А.А., Григорьева Е.Ю.Sycheva N.N., Lipengolts A.A., Skribitsky V.A., Shpakova K.E., Finogenova Y.A., Smirnova A.V., Kasianov A.A., Grigorieva E.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/463

Основным препятствием для распространения бор-нейтронозахватной терапии (БНЗТ) злокачественных опухолей в настоящее время является отсутствие высокоэффективных агентов адресной доставки бора. Уже получившие клиническое применение борфенилаланин и боркаптат натрия обладают существенными недостатками и ограничениями в применении, что поднимает вопрос о необходимости разработки новых лекарственных препаратов для БНЗТ. В данном обзоре рассмотрены актуальные направления разработки борсодержащих лекарственных препаратов для БНЗТ, исследованных на лабораторных животных. В целом, можно выделить три основных направления разработки борсодержащих препаратов для БНЗТ: таргетные препараты на основе антител или лигандов к опухолевым рецепторам (EGFR, VEGFR и др.); природные и неприродные борированные аминокислоты; препараты на основе наноструктур — борсодержащие наночастицы и липосомы. Препараты для БНЗТ должны обладать высокой туморотропностью, то есть обеспечивать концентрацию бора в опухоли не менее не менее 20 мкг на 1 г биологической ткани в течение длительного времени, достаточного для проведения терапевтического облучения, при минимальном накоплении в окружающих здоровых тканях. В обзоре приведен анализ эффективности доставки бора в опухоль данными классами соединений, их перспективности и ограничений. Наиболее перспективным направлением является использование метаболических механизмов доставки бора, например, неприродных циклических аминокислот или трансферрина. Рецептор-опосредованные препараты (лиганды и антитела) к настоящему моменту не подтвердили эффективность доставки бора в количестве, необходимом для проведения БНЗТ.

The primary obstacle to the widespread clinical implementation of Boron Neutron Capture Therapy (BNCT) for malignant tumors is the lack of highly efficient tumor-targeted boron delivery agents. Clinically approved compounds – boronophenylalanine (BPA) and sodium borocaptate (BSH) – exhibit significant limitations, necessitating the development of novel boron pharmaceuticals. This review surveys current research directions in boron-containing drug development for BNCT, focusing on preclinical studies in laboratory animals. Three principal strategies are analyzed: targeted agents (antibody- or ligand-based constructs targeting tumor receptors: EGFR, VEGFR, etc.); natural and unnatural boronated amino acids; nanocarrier-based systems – boron-loaded nanoparticles and liposomes. Effective BNCT agents must demonstrate selective tumor accumulation, achieving intratumoral boron concentrations ≥20 μg/g cancer tissue during neutron irradiation while minimizing accumulation in healthy tissues. We critically evaluate the boron delivery efficacy, the prospects, and limitations of each approach. Current evidence indicates that metabolismdriven delivery systems, such as unnatural cyclic amino acids and transferrin conjugates, show the greatest therapeutic potential. Conversely, receptor-mediated agents (ligands/antibodies) have yet to demonstrate sufficient tumor boron accumulation for clinical BNCT efficacy.

бинарная лучевая терапиянейтронозахватная терапияборсодержащие препаратынаночастицылипосомыагенты доставки борациклические аминокислотыbinary radiotherapyneutron capture therapyboron-containing drugsnanoparticlesliposomesboron delivery agentscyclic amino acidsReferencesLipengolts AA, Finogenova YA, Skribitsky VA, et al. Binary technologies of malignant tumors radiotherapy. J Phys Conf Ser. 2021;2058(1):012039. https://doi.org/10.1088/1742-6596/2058/1/012039Lipengolts AA, Finogenova YA, Skribitsky VA, et al. Binary technologies of malignant tumors radiotherapy. J Phys Conf Ser. 2021;2058(1):012039. https://doi.org/10.1088/1742-6596/2058/1/012039Шейно ИН, Ижевский ПВ, Липенгольц АА, и др. Разработка бинарных технологий лучевой терапии злокачественных новообразований: состояние и проблемы. Бюллетень сибирской медицины. 2017;16(3):192-209. https://doi.org/10.20538/1682-0363-2017-3-192-209Sheino IN, Izhevskiy PV, Lipengolts AA, et al. Development of binary technologies of radiotherapy of malignant neoplasms: condition and problems. Bulletin of Siberian Medicine. 2017;16(3):192-209. (In Russ.). https://doi.org/10.20538/1682-0363-2017-3-192-209Fukuda H. Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results. Cells. 2021;10(11):2881. https://doi.org/10.3390/cells10112881Fukuda H. Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10B-p-Boronophenylalanine (BPA) with Special Reference to the Radiobiological Basis and Clinical Results. Cells. 2021;10(11):2881. https://doi.org/10.3390/cells10112881Липенгольц АА, Григорьева ЕЮ, Иванов СМ, и др. Современное состояние клинической нейтрон-захватной терапии. Онкологический журнал: лучевая диагностика, лучевая терапия. 2018;1(1):15-18. https://doi.org/10.37174/2587-7593-2018-1-1-15-18Lipengolts AA, Grigorieva EY, Ivanov SM, et al. Current Status of Clinical Neutron Capture Therapy. Journal of oncology: diagnostic radiology and radiotherapy. 2018;1(1):15-18. (In Russ.) https://doi.org/10.37174/2587-7593-2018-1-1-15-18Taskaev SY. Boron neutron capture therapy. Phys At Nucl. 2021;84(2):207-11. https://doi.org/10.1134/S106377882101021XTaskaev SY. Boron neutron capture therapy. Phys At Nucl. 2021;84(2):207-11. https://doi.org/10.1134/S106377882101021XMatsumura A, Asano T, Hirose K, et al. Initiatives toward clinical boron neutron capture therapy in Japan. Cancer Biother Radiopharm. 2023;38(3):201-7. https://doi.org/10.1089/cbr.2022.0056Matsumura A, Asano T, Hirose K, et al. Initiatives toward clin‑ ical boron neutron capture therapy in Japan. Cancer Biother Radiopharm. 2023;38(3):201-7. https://doi.org/10.1089/cbr.2022.0056Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun. 2018;38(1):35. https://doi.org/10.1186/s40880-018-0299-7Barth RF, Mi P, Yang W. Boron delivery agents for neutron cap‑ ture therapy of cancer. Cancer Commun. 2018;38(1):35. https://doi.org/10.1186/s40880-018-0299-7Barth RF, Gupta N, Kawabata S. Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun. 2024;44(8):893-909. https://doi.org/10.1002/cac2.12582.Barth RF, Gupta N, Kawabata S. Evaluation of sodium boro‑ captate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of can‑ cer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun. 2024;44(8):893-909. https://doi.org/10.1002/cac2.12582.Yang W, Barth RF, Wu G, et al. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot. 2009;67(7-8):S328-S331. https://doi.org/10.1016/j.apradiso.2009.03.030Yang W, Barth RF, Wu G, et al. Boron neutron capture ther‑ apy of EGFR or EGFRvIII positive gliomas using either bo‑ ronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot. 2009;67(7-8):S328-S331. https://doi.org/10.1016/j.apradiso.2009.03.030Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91(6):2076-80. https://doi.org/10.1073/pnas.91.6.2076Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91(6):2076-80. https://doi.org/10.1073/pnas.91.6.2076Sun T, Li Y, Huang Y, et al. Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy. Oncotarget. 2016;7(28):43095-108. https://doi.org/10.18632/oncotarget.9355Sun T, Li Y, Huang Y, et al. Targeting glioma stem cells enhanc‑ es anti-tumor effect of boron neutron capture therapy. Onco‑ target. 2016;7(28):43095-108. https://doi.org/10.18632/oncotarget.9355Alberti D, Michelotti A, Lanfranco A, et al. In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells. Sci Rep. 2020;10:19274. https://doi.org/10.1038/s41598-020-76370-1Alberti D, Michelotti A, Lanfranco A, et al. In vitro and in vivo BNCT investigations using a carborane containing sulfona‑ mide targeting CAIX epitopes on malignant pleural mesothe‑ lioma and breast cancer cells. Sci Rep. 2020;10:19274. https://doi.org/10.1038/s41598-020-76370-1Trivillin VA, Garabalino MA, Colombo LL, et al. Biodistribution of the boron carriers boronophenylalanine (BPA) and/ or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases. Applied Radiation and Isotopes. 2014;88:94-8. https://doi.org/10.1016/j.apradiso.2013.11.115Trivillin VA, Garabalino MA, Colombo LL, et al. Biodistribu‑ tion of the boron carriers boronophenylalanine (BPA) and/ or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases. Applied Radiation and Isotopes. 2014;88:94-8. https://doi.org/10.1016/j.apradiso.2013.11.115Hübner KF, Thie JA, Smith GT, et al. Positron Emission Tomography (PET) with 1-Aminocyclobutane-1-[11C]carboxylic Acid (1-[11C]-ACBC) for detecting recurrent brain tumors. Clinical Positron Imaging. 1998;1(3):165-73.Hübner KF, Thie JA, Smith GT, et al. Positron Emission Tomog‑ raphy (PET) with 1-Aminocyclobutane-1-[11C]carboxylic Acid (1-[11C]-ACBC) for detecting recurrent brain tumors. Clinical Positron Imaging. 1998;1(3):165-73.Barth RF, Kabalka GW, Yang W, et al. Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas. Applied Radiation and Isotopes. 2014;88:38-42. https://doi.org/10.1016/j.apradiso.2013.11.133Barth RF, Kabalka GW, Yang W, et al. Evaluation of unnatu‑ ral cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas. Applied Radiation and Isotopes. 2014;88:38-42. https://doi.org/10.1016/j.apradiso.2013.11.133Futamura G, Kawabata S, Nonoguchi N, et al. Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma. Radiation Oncology. 2017;12:26. https://doi.org/10.1186/s13014-017-0765-4Futamura G, Kawabata S, Nonoguchi N, et al. Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma. Radiation Oncology. 2017;12:26. https://doi.org/10.1186/s13014-017-0765-4Nakamura H, Koganei H, Miyoshi T, et al. Antitumor effect of boron nitride nanotubes in combination with thermal neutron irradiation on BNCT. Bioorganic & Medicinal Chemistry Letters. 2015;25(2):172-4. https://doi.org/10.1016/j.bmcl.2014.12.005Nakamura H, Koganei H, Miyoshi T, et al. Antitumor effect of boron nitride nanotubes in combination with thermal neu‑ tron irradiation on BNCT. Bioorganic & Medicinal Chemistry Letters. 2015;25(2):172-4. https://doi.org/10.1016/j.bmcl.2014.12.005Menichetti L, De Marchi D, Calucci L, et al. Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3T. Applied Radiation and Isotopes. 2011;69(12):1725-7. https://doi.org/10.1016/j.apradiso.2011.02.032Menichetti L, De Marchi D, Calucci L, et al. Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3T. Applied Radia‑ tion and Isotopes. 2011;69(12):1725-7. https://doi.org/10.1016/j.apradiso.2011.02.032Sumitani S, Oishi M, Yaguchi T, et al. Pharmacokinetics of core-polymerized, boron-conjugated micelles designed for boron neutron capture therapy for cancer. Biomaterials. 2012;33(13):3568-77. https://doi.org/10.1016/j.biomaterials.2012.01.039Sumitani S, Oishi M, Yaguchi T, et al. Pharmacokinetics of core-polymerized, boron-conjugated micelles designed for boron neutron capture therapy for cancer. Biomaterials. 2012;33(13):3568-77. https://doi.org/10.1016/j.biomaterials.2012.01.039Zhang T, Li G, Li S, et al. Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2019;182:110397. https://doi.org/10.1016/j.colsurfb.2019.110397Zhang T, Li G, Li S, et al. Asialoglycoprotein receptor target‑ ed micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma. Col‑ loids Surf B Biointerfaces. 2019;182:110397. https://doi.org/10.1016/j.colsurfb.2019.110397Zhu Y, Lin Y, Zhu YZ, et al. Boron drug delivery via encapsulated magnetic nanocomposites: a new approach for BNCT in cancer treatment. J Nanomater. 2010;2010(1):409320. https://doi.org/10.1155/2010/409320Zhu Y, Lin Y, Zhu YZ, et al. Boron drug delivery via encapsulat‑ ed magnetic nanocomposites: a new approach for BNCT in cancer treatment. J Nanomater. 2010;2010(1):409320. https://doi.org/10.1155/2010/409320Oleshkevich E, Morancho A, Saha A, et al. Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy. Nanomedicine. 2019;20:101986. https://doi.org/10.1016/j.nano.2019.03.008Oleshkevich E, Morancho A, Saha A, et al. Combining mag‑ netic nanoparticles and icosahedral boron clusters in biocom‑ patible inorganic nanohybrids for cancer therapy. Nanomedi‑ cine. 2019;20:101986. https://doi.org/10.1016/j.nano.2019.03.008Feiner IVJ, Pulagam KR, Gómez-Vallejo V, et al. Therapeutic pretargeting with gold nanoparticles as drug candidates for boron neutron capture therapy. Particle & Particle Systems Characterization. 2020;37(12):2000200. https://doi.org/10.1002/ppsc.202000200Feiner IVJ, Pulagam KR, Gómez-Vallejo V, et al. Therapeutic pretargeting with gold nanoparticles as drug candidates for boron neutron capture therapy. Particle & Particle Systems Characterization. 2020;37(12):2000200. https://doi.org/10.1002/ppsc.202000200Pulagam KR, Gona KB, Gómez-Vallejo V, et al. Gold nanoparticles as boron carriers for boron neutron capture therapy: synthesis, radiolabelling and in vivo evaluation. Molecules. 2019;24(19):3609. https://doi.org/10.3390/molecules24193609Pulagam KR, Gona KB, Gómez-Vallejo V, et al. Gold nanopar‑ ticles as boron carriers for boron neutron capture therapy: synthesis, radiolabelling and in vivo evaluation. Molecules. 2019;24(19):3609. https://doi.org/10.3390/molecules24193609Wu CY, Hsieh HH, Chang TY, et al. Development of MRI-detectable boron-containing gold nanoparticle-encapsulated biodegradable polymeric matrix for boron neutron capture therapy (BNCT). Int J Mol Sci. 2021;22(15):8050. https://doi.org/10.3390/ijms22158050Wu CY, Hsieh HH, Chang TY, et al. Development of MRI-de‑ tectable boron-containing gold nanoparticle-encapsulated biodegradable polymeric matrix for boron neutron capture therapy (BNCT). Int J Mol Sci. 2021;22(15):8050. https://doi.org/10.3390/ijms22158050Wu CY, Lin JJ, Chang WY, et al. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT). Colloids Surf B Biointerfaces. 2019;183:110387. https://doi.org/10.1016/j.colsurfb.2019.110387Wu CY, Lin JJ, Chang WY, et al. Development of theranostic ac‑ tive-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT). Colloids Surf B Biointerfac‑ es. 2019;183:110387. https://doi.org/10.1016/j.colsurfb.2019.110387Jain A, Jain SK. Advances in tumor targeted liposomes. Curr Med Chem. 2018;18(1):44-57. https://doi.org/10.2174/1566524018666180416101522Jain A, Jain SK. Advances in tumor targeted liposomes. Curr Med Chem. 2018;18(1):44-57. https://doi.org/10.2174/1566524018666180416101522Tachikawa S, Miyoshi T, Koganei H, et al. Spermidinium closo-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy. Chem Commun. 2014;50(82):12325-8. https://doi.org/10.1039/C4CC04344HTachikawa S, Miyoshi T, Koganei H, et al. Spermidinium clo‑ so-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy. Chem Com‑ mun. 2014;50(82):12325-8. https://doi.org/10.1039/C4CC04344HLee W, Sarkar S, Ahn H, et al. PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020;522(3):669-75. https://doi.org/10.1016/j.bbrc.2019.11.144Lee W, Sarkar S, Ahn H, et al. PEGylated liposome encapsulat‑ ing nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT). Biochem Biophys Res Commun. 2020;522(3):669-75. https://doi.org/10.1016/j.bbrc.2019.11.144Li J, Sun Q, Lu C, et al. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 2022;13(1):2143. https://doi.org/10.1038/s41467-022-29780-wLi J, Sun Q, Lu C, et al. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 2022;13(1):2143. https://doi.org/10.1038/s41467-022-29780-wMaruyama K, Ishida O, Kasaoka S, et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release. 2004;98(2):195-207. https://doi.org/10.1016/j.jconrel.2004.04.018Maruyama K, Ishida O, Kasaoka S, et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-cap‑ ture therapy (BNCT). J Control Release. 2004;98(2):195-207. https://doi.org/10.1016/j.jconrel.2004.04.018Doi A, Kawabata S, Iida K, et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol. 2008;87:287-94. https://doi.org/10.1007/s11060-008-9522-8Doi A, Kawabata S, Iida K, et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transfer‑ rin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol. 2008;87:287-94. https://doi.org/10.1007/s11060-008-9522-8Koganei H, Ueno M, Tachikawa S, et al. Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers. Bioconjug Chem. 2013;24(1):124-32. https://doi.org/10.1021/bc300527nKoganei H, Ueno M, Tachikawa S, et al. Development of high boron content liposomes and their promising antitumor ef‑ fect for neutron capture therapy of cancers. Bioconjug Chem. 2013;24(1):124-32. https://doi.org/10.1021/bc300527nKueffer PJ, Maitz CA, Khan AA, et al. Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes. Proc Natl Acad Sci USA. 2013;110(16):6512-7. https://doi.org/10.1073/pnas.1303437110Kueffer PJ, Maitz CA, Khan AA, et al. Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors follow‑ ing selective delivery of boron by rationally designed lipos‑ omes. Proc Natl Acad Sci USA. 2013;110(16):6512-7. https://doi.org/10.1073/pnas.1303437110Maitz CA, Khan AA, Kueffer PJ, et al. Validation and comparison of the therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes in multiple murine tumor models. Transl Oncol. 2017;10(4):686-92. https://doi.org/10.1016/j.tranon.2017.05.003Maitz CA, Khan AA, Kueffer PJ, et al. Validation and compar‑ ison of the therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes in multiple mu‑ rine tumor models. Transl Oncol. 2017;10(4):686-92. https://doi.org/10.1016/j.tranon.2017.05.003

The authors declare that there are no conflicts of interest present.